ArticleChinese journal of integrative medicine2026
Liangfu Pill Alleviates Constipation-Predominant Irritable Bowel Syndrome through Modulation of 5-HT Signaling Pathway and Gut Microbiota.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the modulation mechanism of Liangfu Pill (LFP) on serotonin (5-HT) signaling pathway and gut microbiota in constipation-predominant irritable bowel syndrome (IBS-C) rat models to clarify its therapeutic effects.
methodsThe major metabolites of LFP were analyzed, and network analysis was used to predict the potential mechanism of LFP on IBS-C. Sixty SD rats were allocated to normal, normal + LFP (N+LFP), model, moxapride, low- and high-dose LFP (LFP-L and LFP-H) groups. IBS-C model was developed by tail-clamping stress, irregular feeding, and ice-water gavage for 14 d. Following 7-d intervention, levels of substance P (SP), vasoactive intestinal peptide (VIP), and melatonin (MLT) in the colon tissues were quantified using ELISA, while high-performance liquid chromatography was used to measure the concentration of 5-HT in colon tissue. The expressions of serotonin transporter (SERT), tryptophan hydroxylase 1 (TPH1), and serotonin 4 receptor (5-HT
resultsChromatographic analysis identified 104 major metabolites in LFP. Network analysis predicted that the main signaling pathways involved serotonergic synapses and regulation of transient receptor potential channels by inflammatory mediators. In rats with IBS-C, LFP increased body weight gain, open-field total distance and average speed, fecal count, Bristol stool score, and the levels of SP and VIP, while decreasing abdominal withdrawal reflex scores and 5-HT level (P<0.05 or P<0.01). The protein expressions of SERT and 5-HT
conclusionsLFP alleviates IBS-C symptoms, improves overall condition and especially reduces visceral sensitivity in rats. The potential mechanism may involve modulation of 5-HT signaling pathway and gut microbiota.
Indexed as
Identifiers
42771291What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.